Trial · NCT00780000
Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer
NCT00780000, Phase 2, Terminated, Bristol-Myers Squibb
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer. Trials, record NCT00780000. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00780000
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer
- NCT number
- NCT00780000
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Breast Cancer
- Interventions
- Alvespimycin
- First posted
- 2008-10-24
- Last updated
- 2015-11-04
- Other registries' IDs
- eudract:2007-003121-25
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective tumor response rate (either RECIST or WHO complete response, partial response or minor response) confirmed by CT and MRI as the preferred methods for tumor assessments and Chest x-ray is acceptable for pulmonary lesions | Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days) | (all patients were off study by June 2008) |
| Secondary | Adverse Events assessed according to the NCI CTCAE (v 3.0) grading system | Within 28 days prior to the start of treatment, and for 167 days | (all patients were off study by June 2008) |
| Secondary | Laboratory tests assessed according to the NCI CTCAE (v 3.0) grading system | Within 10 days prior to Cycle 1/1st infusion; within 48 hours of infusion (Cycle 1/Weeks 2/3/4 and Cycle 2+/Week3), or within 72 hours prior to infusion (Cycle 2+/Week 1) | |
| Secondary | Vital signs | Within 28 days prior to the start of treatment, Day1 of Weeks 1, 2, and 3 of Cycle 1 (4 weeks long), and prior to each 4-week cycle starting with Cycle 2, for 167 days | (all patients were off study by June 2008) |
| Secondary | Karnofsky Performance Status | Within 28 days prior to the start of treatment, prior to each 4-week cycle starting with Cycle 2, for 167 days | (all patients were off study by June 2008) |
| Secondary | Ocular testing | Within 28 days prior to the start of treatment, Cycle 1/Day 10 (3 days +/- 1 day following the 2nd infusion in the first cycle of therapy), prior to Cycle 2, if clinically indicated thereafter, for 167 days | (all patients were off study by June 2008) |
| Secondary | Kaplan-Meier estimate of time to progression | Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days) | (all patients were off study by June 2008) |
| Secondary | Time to progression on the patient's prior cytotoxic chemotherapy compared to the patient's time to progression on alvespimycin | Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days) | (all patients were off study by June 2008) |
| Secondary | Kaplan-Meier estimate of progression-free survival | Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days) | (all patients were off study by June 2008) |
| Secondary | Kaplan-Meier estimate of time to response | Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days) | (all patients were off study by June 2008) |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00780000
GET https://conductscience.org/api/trials/v1/NCT00780000/registered